Literature DB >> 16158928

The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia.

Marc De Braekeleer1, Frédéric Morel, Marie-Josée Le Bris, Angèle Herry, Nathalie Douet-Guilbert.   

Abstract

Reciprocal chromosomal translocations are recurrent features of many hematological malignancies. The cloning of the genes located at the breakpoints of chromosomal translocations in leukemia and lymphoma has led to the identification of new genes involved in carcinogenesis. Molecular studies of the breakpoint of several translocations involving chromosomal band 11q23 led to the cloning of a gene that was named MLL. Based on 7969 cases of acute myeloblastic leukemia (AML) and 1252 cases of acute lymphoblastic leukemia (ALL) taken from the literature, band 11q23 and/or the MLL gene was involved in 5.2% of AML and 22% of ALL. Differences in the frequency and the distribution of translocations were noted according to the type of acute leukemia and age of the patients. Seventy-five different rearrangements involving band 1 q23 have so far been identified, 39 MLL partner genes having been cloned. The fusion of MLL and its partner gene leads to a gain of function of the MLL gene. The accumulating data suggests that the fusion protein affects the differentiation of the hematopoietic pluripotent stem cells or the lymphoid or myeloid committed stem cells by deregulating the HOX gene expression patterns.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16158928

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Authors:  Corina Buechele; Erin H Breese; Dominik Schneidawind; Chiou-Hong Lin; Johan Jeong; Jesus Duque-Afonso; Stephen H K Wong; Kevin S Smith; Robert S Negrin; Matthew Porteus; Michael L Cleary
Journal:  Blood       Date:  2015-08-26       Impact factor: 22.113

2.  Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!

Authors:  Marie C Béné
Journal:  Haematologica       Date:  2009-07       Impact factor: 9.941

3.  Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.

Authors:  Fabiana Perna; Michel Sadelain
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

4.  Identification of MLL partner genes in 27 patients with acute leukemia from a single cytogenetic laboratory.

Authors:  Etienne De Braekeleer; Claus Meyer; Nathalie Douet-Guilbert; Audrey Basinko; Marie-Josée Le Bris; Frédéric Morel; Christian Berthou; Rolf Marschalek; Claude Férec; Marc De Braekeleer
Journal:  Mol Oncol       Date:  2011-08-26       Impact factor: 6.603

Review 5.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

6.  Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.

Authors:  Axel Rolf Zander; Ulrike Bacher; Jürgen Finke
Journal:  Dtsch Arztebl Int       Date:  2008-09-26       Impact factor: 5.594

7.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

8.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.

Authors:  Junping Wei; Mark Wunderlich; Catherine Fox; Sara Alvarez; Juan C Cigudosa; Jamie S Wilhelm; Yi Zheng; Jose A Cancelas; Yi Gu; Michael Jansen; Jorge F Dimartino; James C Mulloy
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

9.  11q23 abnormalities in adult Chinese patients with hematological malignancies.

Authors:  Xiaoli Zhao; Shuang Li; Nianyi Li; Rong Fan; Guowei Lin; Xiaoqin Wang
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

Review 10.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.